Tag:

Eli Lilly

Latest Headlines

Latest Headlines

Eli Lilly continues downward spiral in Q3 as generics slam Cymbalta, Evista sales

Eli Lilly found itself standing at the bottom of a steep slope this year, beleaguered by slumping sales and patent losses for two of its bestselling drugs. The Indianapolis, IN-based company is continuing on its downward spiral, reporting a 16% dip in revenue due to exclusivity losses on anti-depressant Cymbalta and osteoporosis drug Evista.

Lilly bets another $375M on Zymeworks' two-pronged cancer tech

Eli Lilly is expanding its relationship with Canadian biotech Zymeworks, signing a broader deal that promises up to $375 million in milestones for its partner as the two collaborate on cancer immunotherapies.

Lilly closing a Puerto Rico plant next year but investing in another

Puerto Rico, which has seen a number of plant closings recently, is facing another. Eli Lilly said it will close a facility in Guayama next year and put it up for sale.

Lilly will close Puerto Rico plant, affecting 100 workers

It has been a tale of two cities when it comes to Eli Lilly's operations in Puerto Rico. Its plant in Carolina has been slotted for $240 million in investments in the last year, benefiting from its buildup in insulin products, and its plant in Guayama is getting axed, a victim of patent losses.

With help from Eli Lilly, TVM pushes its build-to-buy fund to $201M

Closely allied with Eli Lilly, TVM Capital Life Sciences has bumped up its latest fund past the $200 million mark with plans to bankroll up to 15 build-to-buy drug development projects.

EU green-lights Novartis sale of its animal health business to Eli Lilly

European Union regulators approved the sale of Novartis' animal health business to Eli Lilly in a deal worth $5.4 billion that is expected to propel the U.S. drugmaker closer to the front of the veterinary products line.

UPDATED: Eli Lilly scraps tabalumab for lupus after it flops in (another) PhIII program

Eli Lilly's tabalumab has flopped in another Phase III program, failing to score well enough to survive as a potential new treatment for lupus--a follow-up setback to its earlier failure in rheumatoid arthritis. Lilly now plans to bury the program in its crowded graveyard of late-stage drugs.

Elanco and Dow AgroSciences team up to meet global demand for food

Elanco, the animal health division of Eli Lilly, and Dow AgroSciences said they are partnering to jointly focus on helping producers increase meat and milk production to meet a growing global demand. 

EU panel backs slew of new drugs and uses, boosting Lilly, AZ, Novartis, Gilead and more

When Europe's drug approval gatekeepers meet, they often tick off recommendations for some key Big Pharma products. This week, the Committee for Medicinal Products for Human Use backed a whopping 15 new meds and 3 new indications.

UPDATED: FDA hands Eli Lilly a big win, OKs dulaglutide for diabetes

An embattled Eli Lilly won a major battle today, gaining the FDA's approval to market dulaglutide for Type 2 diabetes. It will be sold as Trulicity.